VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

(2017) R. A. Burger et al.   JOURNAL OF CLINICAL ONCOLOGY

Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

(2017) G. Kristensen et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

(2014) Mario Scartozzi et al.   INTERNATIONAL JOURNAL OF CANCER

The role of semaphorins and their receptors in vascular development and cancer

(2013) Chenghua Gu et al.   EXPERIMENTAL CELL RESEARCH

Should studies of maintenance therapy be maintained in women with ovarian cancer?

(2013) Michael A. Bookman   Journal of Gynecologic Oncology

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target

(2012) B. Sitohy et al.   CANCER RESEARCH

To sprout or to split? VEGF, Notch and vascular morphogenesis

(2011) Roberto Gianni-Barrera et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Semaphorins and tumor angiogenesis

(2009) Guido Serini et al.   ANGIOGENESIS

Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry

(2009) Tao Sun et al.   HEPATOLOGY

Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages

(2008) Jose Rafael Sierra et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Metabolism and Therapeutic Angiogenesis

(2008) Peter Carmeliet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Origins of Cancer

(2008) Harold J. Burstein et al.   NEW ENGLAND JOURNAL OF MEDICINE